BridgeBio Pharma, Inc.
BBIO
$35.24
$0.391.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.71% | 2,285.27% | 2,209.77% | 3,761.22% | 181.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.71% | 2,285.27% | 2,209.77% | 3,761.22% | 181.05% |
| Cost of Revenue | 147.35% | 58.54% | -4.13% | -9.26% | -12.57% |
| Gross Profit | -43.80% | 3,079.58% | 3,006.49% | 7,031.69% | 188.11% |
| SG&A Expenses | 77.82% | 91.87% | 79.23% | 60.19% | 41.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.47% | 31.30% | 35.52% | 39.76% | 33.50% |
| Operating Income | -44.83% | 3.68% | 2.14% | 1.57% | -7.43% |
| Income Before Tax | -23.59% | 17.00% | 28.42% | 21.00% | -28.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.80% | 16.82% | 28.42% | 21.00% | -28.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.87% | -24.52% | -31.54% | -31.32% | 656.92% |
| Net Income | -24.10% | 16.70% | 28.37% | 20.80% | -26.67% |
| EBIT | -44.83% | 3.68% | 2.14% | 1.57% | -7.43% |
| EBITDA | -45.60% | 3.65% | 2.11% | 1.55% | -7.55% |
| EPS Basic | -9.37% | 27.90% | 38.26% | 29.73% | -13.87% |
| Normalized Basic EPS | -35.63% | 9.58% | 12.76% | 12.41% | -16.73% |
| EPS Diluted | -9.37% | 27.90% | 38.26% | 29.73% | -13.87% |
| Normalized Diluted EPS | -35.63% | 9.58% | 12.76% | 12.41% | -16.73% |
| Average Basic Shares Outstanding | 11.62% | 14.33% | 16.53% | 15.33% | 13.48% |
| Average Diluted Shares Outstanding | 11.62% | 14.33% | 16.53% | 15.33% | 13.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |